Oral delivery of antisense conjugates targeting PCSK9
NZ835422APending Publication Date: 2026-07-31CIVI BIOPHARMA INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- NZ835422
- Authority / Receiving Office
- NZ · NZ
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-09-22
- Filing Date
- 2021-12-10
- Publication Date
- 2026-07-31
Smart Images
Figure 00000172_0000 
Figure 00000173_0000 
Figure 00000174_0000
Abstract
The present disclosure provides pharmaceutic compositions for oral delivery comprising an antisense oligonucleotide (e.g., CIVI 008) and an oral delivery agent such as 5-CNAC. In some aspects, the disclosure provides a capsule comprising a dry blend of CIVI 008 and 5-CNAC, and optionally a statin.
Need to check novelty before this filing date? Find Prior Art